千红制药(002550) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 46,245,597.11, down 2.21% year-on-year[8]. - Operating income for the reporting period was CNY 301,323,423.76, representing a decrease of 8.54% compared to the same period last year[8]. - Net profit for the current period was CNY 41,592,149.04, down from CNY 47,225,138.21, representing a decline of 12.4%[63]. - Earnings per share (EPS) for the current period was CNY 0.0383, compared to CNY 0.0371 in the previous period, indicating a slight increase of 3.2%[67]. - The net profit attributable to the parent company was ¥221,085,066.81, an increase from ¥210,743,817.45 in the previous period[81]. - Net profit for the current period was ¥237,122,730.36, compared to ¥223,437,717.55 in the previous period, indicating an increase of 6.1%[89]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,037,609,646.92, a decrease of 4.43% compared to the end of the previous year[8]. - Total liabilities increased from ¥640,112,439.71 to ¥750,130,145.83, an increase of about 17.3%[46]. - The company's equity attributable to shareholders decreased from ¥2,529,786,331.95 to ¥2,288,552,683.03, a decline of approximately 9.5%[49]. - Current liabilities increased from ¥554,881,024.99 to ¥691,213,899.14, an increase of approximately 24.5%[46]. - The total assets decreased to CNY 3,085,766,400.21 from CNY 3,190,197,090.69, a decrease of 3.3%[59]. Cash Flow - Net cash flow from operating activities increased significantly by 272.02% to CNY 79,911,900.21[8]. - Net cash flow from operating activities increased by 170.20 million yuan compared to the same period last year, primarily due to an increase in sales receipts[22]. - Cash flow from operating activities generated ¥136,704,095.40, a significant recovery from a negative cash flow of -¥33,494,839.64 in the previous period[94]. - Total cash inflow from operating activities was ¥1,303,794,802.01, compared to ¥994,752,552.64 in the previous period, an increase of 31.0%[94]. - Cash paid for purchasing goods and services was ¥704,234,274.58, an increase from ¥604,288,893.36, indicating a rise of about 16.5%[103]. Investments and Expenses - Research and development expenses increased by CNY 2,252,100, indicating ongoing investment in project development[21]. - Research and development expenses rose to CNY 21,676,549.66 from CNY 20,379,243.34, an increase of 6.4%[60]. - The company reported a financial expense of CNY -31,191,170.90, an improvement compared to CNY -35,466,087.89 in the previous period[60]. - The company has invested a total of 142.65 million yuan in entrusted financial products, with an overdue amount of 32.06 million yuan[32]. - The company recognized a bad debt provision of 10.41 million yuan for overdue financial products totaling 320.62 million yuan[35]. Shareholder Activities - The net assets attributable to shareholders of the listed company decreased by 241 million yuan, mainly due to the repurchase of 64 million shares, which were recorded as treasury stock[23]. - The company completed its share repurchase plan, acquiring a total of 64 million shares at a total cost of approximately 309.44 million yuan, with a maximum price of 5.20 yuan per share[26]. - The company reported a significant increase in contract liabilities, rising from ¥1,811,874.09 to ¥4,267,551.90, an increase of approximately 135.5%[46]. Inventory and Prepayments - Inventory increased by 30.17% compared to the beginning of the period, reflecting a strategy to enhance stock reserves to meet market demand[21]. - Prepayments increased by 2.46 million yuan compared to the beginning of the period, mainly due to an increase in pre-received sales payments[22]. - Prepayments increased from ¥31,802,114.02 to ¥96,127,420.15, a growth of approximately 202.5%[50].